Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
- PMID: 26696803
- PMCID: PMC4678312
- DOI: 10.1159/000440673
Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
Abstract
Background: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades.
Methods: Serological tests were performed according to standard procedures. Detection of drug-dependent antibodies was performed in the presence and absence of the relevant drug and/or their ex vivo antigens.
Results: Over the last 20 years, 73 patients have been identified with DIHA in our institute, which was related to 15 different drugs. The most common single drugs identified were diclofenac (n = 23), piperacillin (n = 13), ceftriaxone (n = 12) and oxaliplatin (n = 10). As far as data were available, haemolysis was acute in all patients, and signs of intravascular haemolysis were present in 90% of the cases. Haemolysis resulted in death in 17 patients (23%). The remaining patients recovered, but haemolysis was complicated by transitory renal and/or liver failure or shock in 11 patients. Upon initial evaluation, the antibody screening test was positive in 36 cases. A positive direct antiglobulin test (DAT) at least with anti-C3d was found in 65 cases, with anti-IgG only in 6 cases, and with anti-IgA only in 1 case.
Conclusion: DIHA is a rare but potentially life-threatening disorder that should be considered if a patient develops haemolysis under drug treatment. The main serological finding is a positive DAT, primarily with anti-C3d.
Keywords: Anaemia; Complement; Drug-dependent antibodies; Drug-induced haemolysis; Ex vivo antigens; Fatal haemolysis; Intravascular haemolysis.
Similar articles
-
Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature.Intensive Care Med. 2000 Sep;26(9):1390-4. doi: 10.1007/s001340000598. Intensive Care Med. 2000. PMID: 11089773 Review.
-
Diclofenac-induced immune haemolytic anaemia: simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies.Br J Haematol. 1996 Dec;95(4):640-4. doi: 10.1046/j.1365-2141.1996.d01-1947.x. Br J Haematol. 1996. PMID: 8982039
-
Case Report: Drug-Induced Immune Haemolytic Anaemia Caused by Cefoperazone-Tazobactam/ Sulbactam Combination Therapy.Front Med (Lausanne). 2021 Aug 12;8:697192. doi: 10.3389/fmed.2021.697192. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34485334 Free PMC article.
-
Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the 'immune complex' method.Vox Sang. 2002 Oct;83(3):273-8. doi: 10.1046/j.1423-0410.2002.00188.x. Vox Sang. 2002. PMID: 12366773
-
Collage of cases and brief review of the laboratory diagnosis and molecular testing in autoimmune haemolytic anaemia.J Family Med Prim Care. 2024 Feb;13(2):409-416. doi: 10.4103/jfmpc.jfmpc_2131_22. Epub 2024 Mar 6. J Family Med Prim Care. 2024. PMID: 38605807 Free PMC article. Review.
Cited by
-
Ceftriaxone-induced hemolytic anemia managed successfully in a 54-year-old woman: a case report and literature review.Front Pharmacol. 2025 Jan 7;15:1505366. doi: 10.3389/fphar.2024.1505366. eCollection 2024. Front Pharmacol. 2025. PMID: 39840085 Free PMC article.
-
Ceftriaxone-Induced Immune Hemolytic Anemia.Cureus. 2020 Jun 17;12(6):e8660. doi: 10.7759/cureus.8660. Cureus. 2020. PMID: 32699660 Free PMC article.
-
A leap in recognizing drug-induced immune hemolytic anemia.Blood Adv. 2024 Feb 13;8(3):815-816. doi: 10.1182/bloodadvances.2023011842. Blood Adv. 2024. PMID: 38349669 Free PMC article. No abstract available.
-
Beta-lactam-induced severe neutropenia: a descriptive study.Fundam Clin Pharmacol. 2019 Apr;33(2):223-224. doi: 10.1111/fcp.12449. Fundam Clin Pharmacol. 2019. PMID: 30860628 Free PMC article. No abstract available.
-
Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia.Case Rep Oncol. 2016 Jun 27;9(2):373-8. doi: 10.1159/000447508. eCollection 2016 May-Aug. Case Rep Oncol. 2016. PMID: 27462240 Free PMC article.
References
-
- Petz L, Garratty G. Immune Hemolytic Anemias, 2nd ed. Philadelphia, Churchill Livingstone, 2004.
-
- Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Spath-Schwalbe E, Gruneisen A, Mayer B, Salama A, Kurtal H. Drug induced immune haemolytic anaemia in the berlin case-control surveillance study. Br J Haematol. 2011;154:644–653. - PubMed
-
- Salama A, Mayer B. Diagnostic pitfalls of drug-induced immune hemolytic anemia. Immunohematology. 2014;30:80–84. - PubMed
-
- Salama A. Drug-induced immune hemolytic anemia. Exp Opin Drug Saf. 2009;8:73–79. - PubMed
-
- Arndt PA. Drug-induced immune hemolytic anemia: THE last 30 years of changes. Immunohematology. 2014;30:44–54. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous